Acute adverse events in the DESTINATION 1 trial: A prospective prostate SBRT dose de-escalation feasibility study
The DESTINATION study demonstrates that dose de-escalation 5-fraction SBRT with isotoxic focal boost produces acute AE rates similar to or above the levels seen in the PACE-B trial. The focal boost may have offset any potential decrease in AE from whole gland de-escalation.
Authors
- Floris J. Pos (ORCID: https://orcid.org/0000-0002-0903-4149)
- S. Hassan
- U. Oelfke
- Rosalyne Westley (ORCID: https://orcid.org/0000-0001-5242-8736)
- Alex Dunlop (ORCID: https://orcid.org/0009-0002-9105-3249)
- Trina Herbert (ORCID: https://orcid.org/0000-0001-7542-0622)
- S. Alexander
- Simeon Nill (ORCID: https://orcid.org/0000-0003-4351-8136)
- Joel M. Chick
- Sian Cooper (ORCID: https://orcid.org/0009-0001-1016-9841)
- C. P. Cherry
- Mathijs G. Dassen
- Adam Mitchell
- Uulke van der Heide
- Alison Tree
- Francesca Mason
- Danny Vesprini
- Murtaza Saifuddin
Institutions
- Sunnybrook Health Science Centre (CA)
- Royal Marsden NHS Foundation Trust (GB)
- Institute of Cancer Research (GB)
- University of Toronto (CA)
- Health Sciences Centre (CA)
- The Netherlands Cancer Institute (NL)
- Royal Marsden Hospital (GB)
Publication Details
- Journal
- Radiotherapy and Oncology
- Published
- 2026-01-06
- DOI
- https://doi.org/10.1016/j.radonc.2026.111363
- Citations
- 1
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 36.44
Funders
- National Institute for Health and Care Research
- Department of Health and Social Care